Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14038318 | 0.90 | PTGDR2 (0.37) | KMT2AFTOGAAGLA | |
| SCHEMBL3618903 | 0.90 | PTGDR2 (0.37) | KMT2AFTOGAAGLA | |
| SCHEMBL3617799 | 0.87 | ALDH1A1 (0.43) | KMT2ASMN1; SMN2TSHRGAAGLA | |
| SCHEMBL3650395 | 0.83 | PTGDR2 (0.40) | KMT2ATSHRGAAGLA | |
| SCHEMBL3624354 | 0.83 | FTO (0.34) | FTO | |
| SCHEMBL14037706 | 0.83 | ALDH1A1 (0.42) | TSHRGAA | |
| SCHEMBL3619107 | 0.83 | TSHR (0.43) | KMT2AHTTTSHRUSP2FTO | |
| SCHEMBL5053860 | 0.82 | FTO (0.34) | FTO | |
| SCHEMBL5058660 | 0.81 | FTO (0.33) | FTO | |
| SCHEMBL5058693 | 0.81 | FTO (0.33) | FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155178-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | Salutria Pharmaceuticals, LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140781-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | ATHEROGENICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140781-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | ATHEROGENICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | NR3C2, PTGER2, PTGER1 | KMT2A 3821/4885LMNA 1509/4885HTT 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.